Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 25 articles: HTML format Text format

Single Articles

May 2018
1. GARCIA-TSAO G
   Long-term albumin in cirrhosis: is it the ANSWER?
   Lancet. 2018 May 31. pii: S0140-6736(18)30948.
   PubMed     Text format    
   
   
   
2. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
   Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
   Lancet. 2018 May 31. pii: S0140-6736(18)30840.
   PubMed     Text format     Abstract available
   
   
   March 2018
3. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
   NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
   PubMed     Text format     Abstract available
   
   
   February 2018
4. KUDO M, Finn RS, Qin S, Han KH, et al
   Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
   Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
   PubMed     Text format     Abstract available
   
   
   January 2018
5. PATTEN DA, Shetty S
   Chronic liver disease: scavenger hunt for novel therapies.
   Lancet. 2018;391:104-105.
   PubMed     Text format    
   
   
   
6. FORNER A, Reig M, Bruix J
   Hepatocellular carcinoma.
   Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
   PubMed     Text format     Abstract available
   
   
   April 2017
7. WORNS MA, Galle PR
   Immune oncology in hepatocellular carcinoma-hype and hope.
   Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
   PubMed     Text format    
   
   
   
8. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
   Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
   PubMed     Text format     Abstract available
   
   
   February 2017
9. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
   Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
   Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
   PubMed     Text format     Abstract available
   
   
   January 2017
10. SOTIROPOULOS GC, Machairas N, Kostakis ID, Kouraklis G, et al
    The struggle for intensive care coverage after hepatic resections: the Greek reality.
    Lancet. 2017;389:364-365.
    PubMed     Text format    
    
    
    December 2016
11. BRUIX J, Qin S, Merle P, Granito A, et al
    Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2016 Dec 5. pii: S0140-6736(16)32453.
    PubMed     Text format     Abstract available
    
    
    
12. NAULT JC
    The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.
    Lancet. 2016 Dec 5. pii: S0140-6736(16)32480.
    PubMed     Text format    
    
    
    November 2016
13. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed     Text format    
    
    
    October 2016
14. MAO X, Yan C, Li Y, Lin Y, et al
    Pharmacological mechanisms of Euphorbia Pekinensis and Glycyrrhiza acting on hepatocellular carcinoma ascites: a preclinical study.
    Lancet. 2016;388 Suppl 1:S93.
    PubMed     Text format     Abstract available
    
    
    
15. YANG X, Yu D, Ren Y, Wei J, et al
    EPB41, a novel hepatoma susceptibility gene dysregulated by c-Myc: an integrative functional genomics study.
    Lancet. 2016;388 Suppl 1:S89.
    PubMed     Text format     Abstract available
    
    
    
16. ZHANG YF, Shi M, Guo RP
    A novel risk score (MCCT) to guide decision for treatment of advanced hepatocellular carcinoma with transarterial chemoembolisation: a derivation and validation study.
    Lancet. 2016;388 Suppl 1:S35.
    PubMed     Text format     Abstract available
    
    
    August 2016
17. POWELL LW, Seckington RC, Deugnier Y
    Haemochromatosis.
    Lancet. 2016;388:706-16.
    PubMed     Text format     Abstract available
    
    
    June 2016
18. NEWSOME PN, Armstrong MJ, Gaunt P
    Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
    Lancet. 2016;387:2379.
    PubMed     Text format    
    
    
    
19. DALE A, Hartley P, Heneghan C
    Liraglutide for patients with non-alcoholic steatohepatitis.
    Lancet. 2016;387:2378.
    PubMed     Text format    
    
    
    
20. GABORIT B, Darmon P, Ancel P, Dutour A, et al
    Liraglutide for patients with non-alcoholic steatohepatitis.
    Lancet. 2016;387:2378-9.
    PubMed     Text format    
    
    
    May 2016
21. BRIERLEY R, Bosurgi R
    Gastroenterology and hepatology: a call for papers.
    Lancet. 2016;387:1889-1890.
    PubMed     Text format    
    
    
    March 2016
22. CORRIGAN M, Alrubaiy L, China L
    Hepatology training in the UK.
    Lancet. 2016;387:1055.
    PubMed     Text format    
    
    
    November 2015
23. WONG VW, Wong GL
    A LEAN treatment for non-alcoholic steatohepatitis.
    Lancet. 2015 Nov 19. pii: S0140-6736(15)00982.
    PubMed     Text format    
    
    
    
24. ARMSTRONG MJ, Gaunt P, Aithal GP, Barton D, et al
    Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
    Lancet. 2015 Nov 19. pii: S0140-6736(15)00803.
    PubMed     Text format     Abstract available
    
    
    October 2015
25. BERNAL W, Jalan R, Quaglia A, Simpson K, et al
    Acute-on-chronic liver failure.
    Lancet. 2015;386:1576-87.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: